J Urol: Can blue light cystoscopy improve the detection rate of recurrence in patients with non-muscular invasive bladder cancer?

Some studies and recent meta-analysis have shown that compared with white light cystoscopy (WLC), blue light cystoscopy (BLC) is associated with an increase in the detection rate of primary tumors and tumor recurrence, a decrease in recurrence rate and a longer time to first recurrence Related
.

Therefore, the current guidelines of the American Urological Association recommend that clinicians perform blue-light cystoscopy when performing transurethral resections (TURBTs) for patients with non-muscular invasive bladder cancer (NMIBC)

Although the previous consensus statement provided expert advice, there was no guideline for incorporating blue light cystoscopy into the NMIBC patient monitoring program.

After BCG (BCG) treatment, the utility of blue light cystoscopy (BLC) in cystoscopy is not very clear
.

Recently, researchers from the United States published an article in "J Urol" magazine to determine whether BLC can improve the detection rate of recurrence in patients receiving BCG treatment of non-muscle invasive bladder cancer (NMIBC)

Determined whether BLC can increase the detection rate of recurrence in patients receiving BCG in non-muscle invasive bladder cancer (NMIBC)

The researchers used prospective multi-agency Cysview registry data (2014-2019) to include NMIBC patients who received BCG treatment within the first year of BLC
.

The main result is the recurrence and whether the lesion can be detected by white light cystoscopy (WLC), BLC, or both cystoscopy

A total of 1703 cases of BLC were included in the study, and 282 cases of cystoscopy eventually entered the analysis cohort
.

The results showed that the total recurrence detection rate of 282 cases of cystoscopy was 45.

Indications and intervals of 16 patients with recurrence detected by BLC

Indications and intervals of 16 patients with recurrence detected by BLC

To sum up, BLC helps to detect recurrence after recent BCG treatment, while WLC alone will lead to missed diagnosis
.

Therefore, doctors should consider performing BLC for high-risk patients receiving BCG and discuss the risk of false positives with these patients

BLC helps to detect recurrence after recent BCG treatment, but missed diagnosis occurs only with WLC BLC helps to detect recurrence after recent BCG treatment, but missed diagnosis occurs only with WLC

Original source:

Original source:

Meera R Chappidi, Heiko Yang, Maxwell V Meng et al.

Utility of Blue Light Cystoscopy for Post-BCG Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons

 

Leave a message here